Table 1:
Treatment results for B-cell ALL and T-cell ALL in major paediatric clinical trials
| Years of study | Patients (n) | Age range, years | Patients with T-cell ALL (%) | Patients who received cranial irradiation (%) | 5-year event-free survival, % (SE or 95% CI) | 5-year overall survival, % (SE or 95% CI) | References | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total | B-cell | T-cell | Total | B-cell | T-cell | |||||||
| Associazione Italiana di Ematologia Pediatrica Group-Berlin-Frankfurt-Münster 2000 | 2000–06 | 4741 | 1–18 | 13·2% | 18% | NA | 80·4% (0·9) at 7 years | 75·9% (2·0) at 7 years* | NA | 91·8% (0·5) at 7 years | 80·7% (1·9) at 7 years* | Conter et al (2010)4 and Schrappe et al (2011)5 |
| COG (Children’s Cancer Group, Paediatric Oncology Group, COG) studies† | 2000–05 | 7153 | 0–22 | 7·1% | NA | NA | NA | NA | 90·4% (0·5) | 91·1% (0·5) | 81·6% (2·2) | Hunger et al (2012)6 |
| Dutch COG-10 | 2004–12 | 778 | 1–18 | 14·9% | 0·6% | 87·0% (1·2) | 88·4% (1·3) | 80·0% (3·7) | 91·9% (1·0) | 93·3% (1·0) | 84·4% (3·4) | Pieters et al (2016)7 |
| Dana-Farber Cancer Institute Consortium 05–001 | 2005–10 | 551 | 1–18 | 12·5% | Approximately 23% | 85% (82–88) | 85% (82–88) | 87% (76–93) | 91% (88–93) | 91% (88–93) | 91% (81–96) | Place et al (2015)8 |
| European Organisation for Research and Treatment of Cancer-Children’s Leukemia Group 58 951 | 1998–2008 | 1947 | 0–17 | 15·2% | None | 81·3% (0·9) at 8 years | Dexa: 83·4% (1·4), pred: 82·0% (1·4) at 8 years | Dexa: 71·3% (3·8), pred: 76·7% (3·5) at 8 years | 88·1% (0·8) at 8 years | Dexa: 89·6% (1·2), pred: 90·2% (1·1) at 8 years | Dexa: 74·2% (3·8), pred: 82·1% (3·2) at 8 years | Domenech et al (2014)9 |
| Medical Research Council UK ALL 2003 Trial | 2003–11 | 3126 | 1–24 | 12·4% | 2% | 87·3% (86·1–88·5) | 88·1% (86·6–89·5) | 81·2% (77·3–85·1) | 91·6% (90·6–92·6) | 92·4% (91·4–93·4) | 86·4% (82·9–89·9) | Vora et al (2014)10 and Patrick et al (2014)11 |
| Malaysia-Singapore Trial 2003 | 2002–11 | 556 | 0–18 | 8·8% | Approximately 20% | 80·6% (3·5) at 6 years | 80·7% (3·7) at 6 years | 80·5% (11·6) at 6 years | 88·4% (3·1) at 6 years | NA | NA | Yeoh et al (2012)12 |
| Nordic Society of Paediatric Haematology and Oncology ALL 2008 Trial | 2008–14 | 1509 | 1–17 | 15·3% | None | 85% (1) | 86% (1) | 74% (3) | 91% (1) | NA | NA | Toft et al (2018)13 |
| St Jude Children’s Research Hospital Total XV Trial | 2000–07 | 498 | 1–18 | 15·3% | None | 87·3% (84·4–90·2) | 86·9% (3·1) | 78·4% (7·8) | 93·5% (91·3–95·7) | 94·6% (1·9) | 87·6% (6·3) | Pui et al (2009)14 and Pui etal (2015)15 |
ALL=acute lymphoblastic leukaemia. NA=not available. COG=Children’s Oncology Group. Dexa=dexamethasone. Pred=prednisone.
*
Excluded 145 patients not evaluable for minimal residual disease study, 18 of whom died or relapsed before day 78 of induction.
†
Children’s Cancer Group 1961–91; Pediatric Oncology Group 9494/9407/9904/9905/9906; COG AALL00P2/0232.